<DOC>
	<DOCNO>NCT01256736</DOCNO>
	<brief_summary>The purpose study evaluate 1 year extension study efficacy safety treatment tocilizumab patient complete treatment CWP-TCZ301 study moderate severe active RA inadequate response current DMARD .</brief_summary>
	<brief_title>To Evaluate 1 Year Extension Study Efficacy Safety Tocilizumab Patients With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients Who satisfy in/exclusion criterion CWPTCZ301 Patients withdrawn receive escape therapy complete treatment 24weeks CWPTCZ301 study Patients able enroll study within 12 week last infusion CWPTCZ301 Willing give write informed consent History severe allergic anaphylactic reaction Investigational product CWPTCZ301 study ALT AST &gt; ULNⅹ2.5 Platelet count &lt; 100ⅹ103/ μL WBC &lt; 3,000/mm3 Absolute neutrophil count &lt; 1,000/mm3 Absolute lymphocyte count &lt; 500/mm3 Total bilirubin &gt; ULNⅹ2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>